Compare AMTB & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | MNKD |
|---|---|---|
| Founded | 1979 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.1M | 877.0M |
| IPO Year | 2018 | 2004 |
| Metric | AMTB | MNKD |
|---|---|---|
| Price | $22.51 | $3.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $23.67 | $8.69 |
| AVG Volume (30 Days) | 201.2K | ★ 6.0M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 386.36 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $8.29 | $35.81 |
| Revenue Next Year | $7.67 | $11.89 |
| P/E Ratio | $50.80 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $15.62 | $2.23 |
| 52 Week High | $24.38 | $6.51 |
| Indicator | AMTB | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 59.70 |
| Support Level | $21.98 | $2.45 |
| Resistance Level | $22.75 | $6.08 |
| Average True Range (ATR) | 0.57 | 0.26 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 49.13 | 34.25 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.